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We read the Review on neuro-
ﬁ bromatosis type 1 (NF1) by Angela 
Hirbe and David Gutmann1 with great 
interest. Although Hirbe and Gutmann 
precisely described the genetic, 
phenotypic, and skin features, their 
focus is on the less frequent clinical 
manifestations including dysplastic 
abnormalities of the central and 
peripheral nervous system, changes 
to musculoskeletal and  respiratory 
systems, and the occurrence 
of CNS and non-CNS tumours. 
Cardiac and peripheral vascular 
disorders are also possible clinical 
complications in NF1 that require 
speciﬁ c discussion.2 Our experience 
shows that vascular complications 
in NF1 can occur in diﬀ erent sites 
and can evolve rapidly, with patients 
developing new aneurysms, even 
after endovascular treatment. 
Cardiovascular abnormalities are often 
underestimated because a diagnosis 
is usually made only in patients 
with speciﬁ c clinical manifestations. 
Echocardiograph data suggest that 
up to 27% of patients with NF1 have 
cardiac involvement, with a half of 
patients having pulmonary artery 
stenosis.3
NF1-related vasculopathy includes 
renal and cerebral artery stenosis, 
aortic coarctation, and arteriovenous 
malformations. The pathogenesis, 
clinical features, and natural history 
of these anomalies remain poorly 
understood; however, impaired 
NF1 gene function in vascular 
endothelial cells has been shown to 
increase proliferation and growth.1–3 
Vasculopathy usually aﬀ ects the arterial 
system, leading to cerebrovascular 
disease (eg, narrowed or ectatic blood 
vessels, vascular stenosis, aneurysm, 
or moyamoya disease) or renal artery 
stenosis. Stenotic lesions are the most 
common and are caused mostly by 
intimal proliferation with resulting 
luminal obstruction; the renal artery is 
the most frequent site involved, and 
renovascular hypertension is the most 
common clinical presentation.4   
Investigators have noted intimal 
thickening, thinning of the media, 
and parietal dilatation in small 
vessels of patients with NF1.5,6 Many 
other vessels such as the aorta, and 
intercostal, subclavian, brachial, 
radial, and vertebral arteries can be 
aﬀ ected by aneurysmal dilatations.4,6–8 
Lumbar arteries are rarely involved, 
with only one case described.9 Patients 
with NF1 can have aneurysms, but 
the synchronous involvement of two 
diﬀ erent circulatory regions is not yet 
known.8 However, the real incidence 
of these abnormalities is indeed 
unknown because many lesions are 
undetected.
Traditional surgery with arterial 
clipping and aneurysmal excision 
is the only available option for 
treatment; in patients with NF1, 
complications are of major concern 
because of the fragility of the 
dysplastic vessels. Endovascular 
treatments, such as coil transarterial 
embolisation or percutaneous stent-
graft placement, are sometimes 
considered preferable when it is 
mandatory to maintain an eﬃ  cient 
blood ﬂ ow in the regions perfused 
by the treated vessel; these are less 
invasive and have low intra-operative 
and post-operative mortality.10  
Clinicians must be aware of the 
diverse clinical features, particularly 
with vascular complication and 
recurrence, of NF1. Prompt diagnosis 
is needed to provide optimum care, 
and serial diagnostic procedures are 
needed to increase awareness, to 
avoid early and late adverse events, 
and to prevent deleterious outcomes.
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We read with great interest the Review 
about neuroﬁ bromatosis type 1 (NF1) 
by Angela Hirbe and David Gutmann.1 
Although the Review has much neuro-
oncological detail, we would like to 
make some comments about the 
outlined diagnostic approach, on the 
basis of our clinical experience.
The diagnostic criteria for 
NF1 were drawn up in 1988 at 
the National Institute of Health 
Consensus Conference.2 Since then, 
understanding of the disease has 
improved. Over the past 26 years, the 
gene for NF1 has been discovered, 
observations have been made of 
further clinical features such as 
choroidal hamartomas, unidentiﬁ ed 
bright objects, anaemic nevi, 
glomus tumours, and juvenile 
xanthogranulomas,3–5 and histological 
and molecular assessments of freckles 
have revealed that they do not diﬀ er 
